Hayat Pharmaceutical Industries Adjusts Evaluation Amidst Stable Financial Metrics and Growth Indicators

Hayat Pharmaceutical Industries Co. has recently undergone an adjustment in its evaluation, reflecting changes in various financial metrics. The company's quality grade has been revised, indicating a shift from an excellent to a good standing. This adjustment comes as the firm reported a sales growth of 0.63% over the past five years and an EBIT growth of 3.45%. In terms of financial stability, Hayat maintains a debt to EBITDA ratio of 0.0, suggesting a low level of debt relative to earnings. The net debt to equity ratio stands at -0.14, which indicates a strong equity position. The company has also demonstrated a return on capital employed (ROCE) of 13.28% and a return on equity (ROE) of 10.21%, both of which are noteworthy indicators of its operational efficiency. On the technical front, the stock's trend has shifted to a bullish stance, with various indicators reflecting a positive outlook. Additionally, the valuation grade has been adjusted to very attractive, highlighting the company's favorable position in the market. For more insights into Hayat Pharmaceutical Industries Co. and its financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.